41 related articles for article (PubMed ID: 9892267)
1. Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression.
Jankowski J; van der Giet M; Jankowski V; Schmidt S; Hemeier M; Mahn B; Giebing G; Tolle M; Luftmann H; Schluter H; Zidek W; Tepel M
J Clin Invest; 2003 Jul; 112(2):256-64. PubMed ID: 12865413
[TBL] [Abstract][Full Text] [Related]
2. Metabolomic profiling of amines in sepsis predicts changes in NOS canonical pathways.
Tesfai A; MacCallum N; Kirkby NS; Gashaw H; Gray N; Want E; Quinlan GJ; Mumby S; Leiper JM; Paul-Clark M; Ahmetaj-Shala B; Mitchell JA
PLoS One; 2017; 12(8):e0183025. PubMed ID: 28813479
[TBL] [Abstract][Full Text] [Related]
3. Differences in Dialysis Center Practices in Determining Hemodialysis Patient Postdialysis Target Weight and Patient Survival and Hospitalizations.
Davenport A
Clin J Am Soc Nephrol; 2019 Mar; 14(3):321-323. PubMed ID: 30723165
[No Abstract] [Full Text] [Related]
4. Different Interdialytic Intervals and Cardiorespiratory Fitness in Patients Undergoing Hemodialysis.
Pella E; Boulmpou A; Boutou A; Theodorakopoulou MP; Haddad N; Karpetas A; Giamalis P; Papagianni A; Papadopoulos CE; Vassilikos V; Sarafidis P
Clin J Am Soc Nephrol; 2024 Jun; 19(6):732-742. PubMed ID: 38407848
[TBL] [Abstract][Full Text] [Related]
5. Interaction of Human Serum Albumin with Uremic Toxins: The Need of New Strategies Aiming at Uremic Toxins Removal.
Zare F; Janeca A; Jokar SM; Faria M; Gonçalves MC
Membranes (Basel); 2022 Feb; 12(3):. PubMed ID: 35323736
[TBL] [Abstract][Full Text] [Related]
6. The Influence of Sevelamer Hydrochloride and Calcium Carbonate on Markers of Inflammation and Oxidative Stress in Hemodialysis at Six Months of Follow-Up.
Díaz-De la Cruz EN; Cerrillos-Gutiérrez JI; García-Sánchez A; Prado-Nevárez CG; Andrade-Sierra J; Jalomo-Martínez B; Banda-López A; Rojas-Campos E; Miranda-Díaz AG
Front Med (Lausanne); 2021; 8():714205. PubMed ID: 34901050
[TBL] [Abstract][Full Text] [Related]
7. The effect of hemodialysis on ocular changes in patients with the end-stage renal disease.
Sun G; Hao R; Zhang L; Shi X; Hei K; Dong L; Wei F; Jiang A; Li B; Li X; Ke Y
Ren Fail; 2019 Nov; 41(1):629-635. PubMed ID: 31269848
[No Abstract] [Full Text] [Related]
8. The renal transport protein OATP4C1 mediates uptake of the uremic toxin asymmetric dimethylarginine (ADMA) and efflux of cardioprotective L-homoarginine.
Taghikhani E; Maas R; Fromm MF; König J
PLoS One; 2019; 14(3):e0213747. PubMed ID: 30865704
[TBL] [Abstract][Full Text] [Related]
9. Doppler ultrasound evaluation of morphological and hemodynamical changes of hepatic and mesenteric structures in end-stage renal disease patients on regular hemodialysis.
Ergun T; Lakadamyali H
Int Urol Nephrol; 2010 Mar; 42(1):205-10. PubMed ID: 19629742
[TBL] [Abstract][Full Text] [Related]
10. Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review.
Jacobi J; Tsao PS
Am J Nephrol; 2008; 28(2):224-37. PubMed ID: 17960061
[TBL] [Abstract][Full Text] [Related]
11. Effect of haemodialysis on retinal circulation in patients with end stage renal disease.
Nagaoka T; Takeyama Y; Kanagawa S; Sakagami K; Mori F; Yoshida A
Br J Ophthalmol; 2004 Aug; 88(8):1026-9. PubMed ID: 15258019
[TBL] [Abstract][Full Text] [Related]
12. Response of asymmetric dimethylarginine to hemodialysis-associated hypotension in end-stage renal disease patients.
Csiky B; Sulyok E; Lakatos O; Wittmann I; Martens-Lobenhoffer J; Bode-Boger SM
Nephron Clin Pract; 2008; 108(2):c127-34. PubMed ID: 18230915
[TBL] [Abstract][Full Text] [Related]
13. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease.
Kielstein JT; Böger RH; Bode-Böger SM; Schäffer J; Barbey M; Koch KM; Frölich JC
J Am Soc Nephrol; 1999 Mar; 10(3):594-600. PubMed ID: 10073610
[TBL] [Abstract][Full Text] [Related]
14. Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease.
Kielstein JT; Bode-Böger SM; Frölich JC; Haller H; Böger RH
Kidney Int Suppl; 2001 Feb; 78():S9-13. PubMed ID: 11168975
[TBL] [Abstract][Full Text] [Related]
15. Implications for the role of endogenous nitric oxide inhibitors in hemodialysis hypotension.
Kang ES; Acchiardo SR; Kang AH
Free Radic Res; 2001 Oct; 35(4):341-65. PubMed ID: 11697132
[TBL] [Abstract][Full Text] [Related]
16. Hemodialysis hypotension: interaction of inhibitors, iNOS, and the interdialytic period.
Kang ES; Tevlin MT; Wang YB; Chiang TM; Cardenas R; Myers LK; Acchiardo SR
Am J Med Sci; 1999 Jan; 317(1):9-21. PubMed ID: 9892267
[TBL] [Abstract][Full Text] [Related]
17. Reversible sequestration of nitric oxide by hemoglobin during hemodialysis in end-stage renal disease.
Kang ES; Miles DE; Tevlin MT; Cates TB; Acchiardo SR
Am J Med Sci; 2001 Feb; 321(2):113-23. PubMed ID: 11217813
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
